Valuation: AbbVie Inc.

Capitalization 356B 302B 276B 261B 487B 33,640B 492B 3,278B 1,279B 16,146B 1,336B 1,308B 55,772B P/E ratio 2026 *
24.6x
P/E ratio 2027 * 18.3x
Enterprise value 410B 348B 318B 301B 561B 38,748B 566B 3,775B 1,473B 18,597B 1,539B 1,506B 64,240B EV / Sales 2026 *
6.1x
EV / Sales 2027 * 5.51x
Free-Float
96.03%
Yield 2026 *
3.41%
Yield 2027 * 3.59%
1 day-0.57%
1 week-2.44%
Current month-4.62%
1 month-4.75%
3 months-9.79%
6 months-8.04%
Current year-11.79%
1 week 200.02
Extreme 200.02
209.52
1 month 190.75
Extreme 190.75
214.87
Current year 190.75
Extreme 190.75
237.11
1 year 176.57
Extreme 176.57
244.81
3 years 130.96
Extreme 130.9601
244.81
5 years 105.56
Extreme 105.56
244.81
10 years 55.06
Extreme 55.0623
244.81
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Compliance Officer - 01/01/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 68 01/01/2013
Change 5d. change 1-year change 3-years change Capi.($)
-0.57%-2.44%+8.61%+36.69% 356B
-2.72%-1.54%+26.22%+119.18% 846B
-0.53%-2.58%+42.18%+36.36% 533B
-0.94%-0.97%+21.32%+10.98% 324B
+0.23%-1.24%+31.68%+11.93% 282B
+0.05%-2.19%+24.42%+20.97% 278B
-0.82%-0.70%+43.44%-5.91% 275B
-1.76%+4.42%-32.32%-49.34% 203B
+0.79%+0.57%+21.93%+41.38% 179B
-2.04%-0.24%+33.79%+67.11% 163B
Average -0.83%-0.69%+22.13%+28.93% 343.89B
Weighted average by Cap. -1.10%-1.22%+24.77%+44.41%

Financials

2026 *2027 *
Net sales 67.21B 57.04B 52.17B 49.32B 91.92B 6,350B 92.79B 619B 241B 3,047B 252B 247B 10,527B 72.61B 61.62B 56.36B 53.28B 99.3B 6,859B 100B 668B 261B 3,292B 272B 267B 11,372B
Net income 14.93B 12.67B 11.59B 10.95B 20.41B 1,410B 20.61B 137B 53.62B 677B 56B 54.82B 2,338B 19.32B 16.4B 15B 14.18B 26.43B 1,825B 26.67B 178B 69.41B 876B 72.49B 70.97B 3,026B
Net Debt 54.06B 45.88B 41.96B 39.67B 73.94B 5,107B 74.63B 498B 194B 2,451B 203B 199B 8,468B 44.23B 37.54B 34.33B 32.46B 60.5B 4,179B 61.06B 407B 159B 2,006B 166B 162B 6,928B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
08/05/26 201.55 $ -0.57% 4,915,719
07/05/26 202.71 $ -1.13% 6,681,070
06/05/26 205.03 $ -0.52% 7,289,987
05/05/26 206.11 $ -0.98% 4,490,528
04/05/26 208.16 $ +0.76% 4,579,477
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
201.55USD
Average target price
252.23USD
Spread / Average Target
+25.15%

Quarterly revenue - Rate of surprise